HLA-DQ2 peptide vaccine companion diagnostic - ImmusanT

Drug Profile

HLA-DQ2 peptide vaccine companion diagnostic - ImmusanT

Alternative Names: Nexvax2 Diagnostic - ImmusanT

Latest Information Update: 17 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmusanT
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Coeliac disease

Most Recent Events

  • 08 May 2017 Phase I development is ongoing in Coeliac disease (Diagnosis)
  • 08 May 2017 Phase-I clinical trials in Coeliac disease (Diagnosis) (unspecified route) before May 2017 (ImmusanT company pipeline, May 2017).
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Coeliac disease(Diagnosis) in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top